This is the largest cohort reported so far on the effects of MEK and BRAF inhibitors on sodium and glucose homeostasis for a range of indications being represented, thus allowing the frequency of off-target effects of molecular therapies to be estimated in populations other than low-grade gliomas. This evidence concerns the gene BRAF and central nervous system cancer.